Tetrazole derivatives
US-2024382468-A2 · Nov 21, 2024 · US
Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US9023318B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9023318-B2 |
| Application number | US-201313849646-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 25, 2013 |
| Priority date | Jun 8, 2011 |
| Publication date | May 5, 2015 |
| Grant date | May 5, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatment and the in vivo diagnostic imaging of a range of disease states (inflammatory, malignant and degenerative diseases) where specific matrix metalloproteinases are known to be involved.
First claim
Opening claim text (preview).
We claim: 1. A pharmaceutically acceptable salt of: or a stereoisomer thereof. 2. A compound that is: or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Z is a halo or a radionuclide. 3. A compound that is: or a pharmaceutically acceptable salt or stereoisomer thereof. 4. A pharmaceutically acceptable salt of Formula (IA): or a stereoisomer thereof; wherein X 1 is selected from the group consisting of halo, fluorophore or radioactive halo. 5. The compound of claim 4 , wherein X 1 is F. 6. The compound of claim 4 , wherein X 1 is 18 F.
Assignees
Inventors
Classifications
containing three or more hetero rings · CPC title
only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers · CPC title
- C07D403/14Primary
containing three or more hetero rings · CPC title
1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles · CPC title
having hetero atoms attached to the substituent nitrogen atom (nitro radicals C07D213/26) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9023318B2 cover?
- Novel compounds and pharmaceutical compositions having MMP inhibitory activity are disclosed, which have been found to be particularly useful in the prevention, treatment and diagnostic imaging of diseases associated with an unpaired activity of MMP, amongst others MMP-2, MMP-8, MMP-9 and/or MMP-13 to name a few. The compounds of the present invention are useful for the prevention, the treatmen…
- Who is the assignee on this patent?
- Chen Gang, Gangadharmath Umesh B, Kasi Dhanalakshmi, and 17 more
- What technology area does this patent fall under?
- Primary CPC classification C07D403/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 05 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).